US2021330636A1PendingUtilityA1
Use of cannabidiol in the treatment of epilepsy
Est. expiryOct 14, 2034(~8.2 yrs left)· nominal 20-yr term from priority
A61K 36/3482A61K 31/658A61K 47/26A61P 25/10A61K 47/10A61K 9/08A61K 45/06A61P 25/12A61K 47/44A61P 25/08A61K 31/05A61K 31/352
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Lennox-Gastaut syndrome; Dravet syndrome; or Acardi syndrome.
Claims
exact text as granted — not AI-modified1 . A method of reducing convulsive seizure frequency in a patient with a treatment-resistant epilepsy, which is Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC), wherein the dose of the CBD ranges from 5-25 mg/kg/day.
2 . A method of treating seizures in a subject having Aicardi Syndrome, comprising administering to the subject in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 95 (w/w), and the dose of CBD ranges from about 5-25 mg/kg/day.
3 . The method of claim 2 , wherein the seizures are convulsive seizures.
4 . The method of claim 2 , wherein the seizures are focal seizures with impairment.
5 . The method of claim 2 , wherein the seizures are infantile spasms.
6 . The method of claim 2 , wherein the seizures are treatment resistant.
7 . The method of claim 2 , wherein the CBD is a highly purified extract of cannabis which has a purity of at least 98% (w/w).
8 . The method of claim 7 , wherein the extract comprises less than 0.15% tetrahydrocannabinol (THC).
9 . The method of claim 7 , wherein the extract further comprises up to 1% cannabidivarin (CBDV).
10 . The method of claim 2 , wherein the CBD is present as a synthetic compound.
11 . The method of claim 2 , wherein the dose of the CBD is 10 mg/kg/day.
12 . The method of claim 2 , wherein the dose of the CBD is 12 mg/kg/day.
13 . The method of claim 2 , wherein the dose of the CBD is 14 mg/kg/day.
14 . The method of claim 2 , wherein the dose of CBD is 15 mg/kg/day.
15 . The method of claim 2 , wherein the dose of the CBD is 16 mg/kg/day.
16 . The method of claim 2 , wherein the dose of the CBD is 18 mg/kg/day.
17 . The method of claim 2 , wherein the dose of the CBD is 20 mg/kg/day.
18 . The method of claim 24 , wherein the CBD is administered as a composition, comprising cannabidiol (CBD), a solvent, a co-solvent, a sweetener, and a flavoring.
19 . The method of claim 18 , wherein the solvent is sesame oil.
20 . The method of claim 18 , wherein the co-solvent is ethanol.
21 . The method of claim 18 , wherein the sweetener is sucralose.
22 . The method of claim 18 , wherein the CBD is present at a concentration of ranging from about 25 mg/ml and to about 100 mg/ml.
23 . The method of claim 2 , wherein the patient is administered a starting dose of 5 mg/kg/day, and then the dose is increased by about 2-5 mg/kg up to a maximum of 25 mg/kg/day.
24 . The method of claim 23 , wherein the dose of the CBD is increased up to 10 mg/kg/day.
25 . The method of claim 23 , wherein the dose of the CBD is increased up to 12 mg/kg/day.
26 . The method of claim 23 , wherein the dose of the CBD is increased up to 14 mg/kg/day.
27 . The method of claim 23 , wherein the dose of CBD is increased up to 15 mg/kg/day.
28 . The method of claim 23 , wherein the dose of the CBD is increased up to 16 mg/kg/day.
29 . The method of claim 23 , wherein the dose of the CBD is increased up to 18 mg/kg/day.
30 . The method of claim 23 , wherein the dose of the CBD is increased up to 20 mg/kg/day.Join the waitlist — get patent alerts
Track US2021330636A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.